Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684905 · ClinicalTrials.gov registry record · Phase 2
Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00684905: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00684905 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00684905, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide and bicalutamide, may lessen the amount of androgens made by the body. Implant radiation therapy kills tumor cells by placing material such as radioactive iodine directly into or near a tumor. Giving leuprolide and bicalutamide together with implant radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving leuprolide and bicalutamide together with implant radiation therapy and to see how well it works in treating patients with locally recurrent prostate cancer after external-beam radiation therapy.
Interventions
- DRUG leuprolide acetate
- PROCEDURE quality-of-life assessment
- PROCEDURE adjuvant therapy
- DRUG bicalutamide
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2000-04 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00684905
The ClinicalTrials.gov registry entry for NCT00684905 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which leuprolide acetate is the first listed.
NCT00684905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00684905 about?
NCT00684905 is a clinical study titled "Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy". RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide and bicalutamide, may lessen the amount of androgens made by the body. Implant radiation therapy kills tumor cells by placing material such as radioactive iodine directly into or near a tumor....
What is the current status of trial NCT00684905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2000-04. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00684905?
The interventions under investigation include: leuprolide acetate (DRUG), quality-of-life assessment (PROCEDURE), adjuvant therapy (PROCEDURE), bicalutamide (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00684905?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.